Research map: Inflammatory Cell Profiles in Early- and Late-Manifestation Immune Checkpoint Inhibitor Myocarditis

Back to the article

Papers in this map

  1. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases · Alida L.P. Caforio · 2013 · 3499 citations · Cited by this paper
  2. Late-onset immune checkpoint inhibitor-associated myocarditis: A systematic review and patient-level synthesis · Priyanth Alaguraja · 2026 · Cites this paper
  3. CRISPR/Cas9 Screens Implicate RARA and SPNS1 in Doxorubicin Cardiotoxicity · 2026 · Related
  4. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) · Alexander Richard Lyon · 2022 · 3064 citations · Cited by this paper
  5. Sacubitril/Valsartan in Anthracycline-Treated Patients · 2026 · Related
  6. Fulminant Myocarditis with Combination Immune Checkpoint Blockade · Douglas Buckner Johnson · 2016 · 2337 citations · Cited by this paper
  7. Major Adverse Cardiovascular Events and Cardiac Dysfunction in Patients With Acute Leukemia · 2026 · Related
  8. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update · Bryan J. Schneider · 2021 · 2223 citations · Cited by this paper
  9. Screened But Unproven · 2026 · Related
  10. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study · Joe‐Elie Salem · 2018 · 1266 citations · Cited by this paper
  11. Treatment and Outcomes in Myocardial Infarction and Cancer—A German Real-Life Analysis · 2026 · Related
  12. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis · Javid J. Moslehi · 2018 · 947 citations · Cited by this paper
  13. Sotatercept for the Treatment of Myeloproliferative Neoplasm–Associated Group 5 Pulmonary Hypertension · 2026 · Related
  14. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper · Stéphane Champiat · 2015 · 913 citations · Cited by this paper
  15. The Promise and Pitfalls of TTR Stabilization Assays in ATTR-CM · 2026 · Related
  16. The Next Decade of Immune Checkpoint Therapy · Padmanee Sharma · 2021 · 784 citations · Cited by this paper
  17. Elevated Plasma IL-18 Levels During Chemotherapy Treatment for Breast Cancer, Exercise Capacity, and Physical Activity · 2026 · Related
  18. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment · Nicolas L. Palaskas · 2020 · 540 citations · Cited by this paper
  19. Proactive Surveillance for ICI Cardiotoxicity · 2026 · Related
  20. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity · Marion Escudier · 2017 · 527 citations · Cited by this paper
  21. Reply · 2026 · Related
  22. Myocarditis in the Setting of Cancer Therapeutics · Marc P. Bonaca · 2019 · 462 citations · Cited by this paper
  23. Native T1 Mapping and Extracellular Volume Mapping for the Assessment of Diffuse Myocardial Fibrosis in Dilated Cardiomyopathy · Shiro Nakamori · 2017 · 264 citations · Cited by this paper
  24. Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms · Javid J. Moslehi · 2021 · 235 citations · Cited by this paper
  25. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis · Paaladinesh Thavendiranathan · 2021 · 198 citations · Cited by this paper
  26. Immune Checkpoint Inhibitor–Induced Cardiotoxicity · Dorte Lisbet Nielsen · 2024 · 113 citations · Cited by this paper
  27. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors · Charles Dolladille · 2020 · 95 citations · Cited by this paper
  28. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program · Abdul Rafeh Naqash · 2022 · 84 citations · Cited by this paper
  29. Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy · Sienna Durbin · 2025 · 61 citations · Cited by this paper
  30. Severe vs Nonsevere Immune Checkpoint Inhibitor-Induced Myocarditis · Osnat Itzhaki Ben Zadok · 2023 · 47 citations · Cited by this paper
  31. Steroids in Immune Checkpoint Inhibitor Myocarditis · Nicolas L. Palaskas · 2024 · 27 citations · Cited by this paper
  32. Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation · Andrew Nguyen · 2022 · 20 citations · Cited by this paper
  33. Untitled · Cited by this paper
  34. Untitled · Cited by this paper
  35. Untitled · Cited by this paper
  36. Untitled · Cited by this paper

Source: OpenAlex (CC0)